Maxcyte Inc (MXCT) Stock Price, Quote & News

Company Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications;...

Industry: Medical Devices

Sector: Healthcare

Phone: 301 944 1700

Website: www.maxcyte.com

Address:

9713 Key West Avenue, Suite 400, Rockville, United States

BeefStewart Feb. 13 at 3:48 PM

$MXCT I worried for a moment. I thought things were actually starting to turn around, but now I see it's business as usual and the stock is plunging again on no news 🙄

0 · Reply

CH_Expat Feb. 13 at 2:39 PM

$MXCT No offense dude, but you are way too much into fundamentals as if this was a normal stock. But it is not. It is a joke. Way undervalued, but still a joke. There will a vicious five day run in no news. If you really have a strong conviction in this company, I really feel for you considering there are many good companies out there.

2 · Reply

BeefStewart Feb. 12 at 11:11 PM

$MXCT I view $VRTX earnings as highly validating for MaxCyte. Casgevy is emerging and is nowhere near its potential; but there is plenty of opportunity for sales to reaach 1B+ Within 2 or so years, in my opinion. Further, this is just from one SPL partner. We are early here, in my view, but I believe MaxCyte’s biz model can be fruitful if management gets their act together...

0 · Reply

BeefStewart Feb. 12 at 9:18 PM

$MXCT $VRTX

0 · Reply

BeefStewart Feb. 12 at 9:02 PM

$MXCT

0 · Reply

BeefStewart Feb. 12 at 7:19 PM

$MXCT $VRTX At this point, I think direction is more valuable than absolute revenue from Casgevy. We want to see better cell collection and more treatment centers coming online.

0 · Reply

BeefStewart Feb. 12 at 6:02 PM

$MXCT Could we have actually, finally bottomed at $0.6806???

1 · Reply

BeefStewart Feb. 12 at 5:54 PM

$MXCT Initiate a Strategic Review. Buy back $5-$10M worth of shares. Entertain buyout offers of $2+ once the first 2 steps organically bring the share price over a dollar.

0 · Reply

Playtheplayers Feb. 12 at 5:16 PM

$MXCT thank you...

0 · Reply

BeefStewart Feb. 12 at 5:03 PM

$MXCT If this went to 0.01, would management do a share buyback? 🤔

1 · Reply

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

Dec 1, 2025, 9:00 AM EST - 2 months ago

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

Nov 12, 2025, 7:11 PM EST - 3 months ago

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:08 PM EST - 3 months ago

MaxCyte Announces Planned CFO Transition in 2026

Nov 12, 2025, 4:05 PM EST - 3 months ago

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Nov 5, 2025, 8:05 AM EST - 3 months ago

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Oct 8, 2025, 8:05 AM EDT - 4 months ago

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 6, 2025, 8:05 AM EDT - 4 months ago

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

Sep 22, 2025, 4:30 PM EDT - 5 months ago

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Aug 7, 2025, 3:45 AM EDT - 6 months ago

MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:05 AM EDT - 6 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio

Jul 31, 2025, 8:05 AM EDT - 7 months ago

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

Jul 9, 2025, 8:05 AM EDT - 7 months ago

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 1, 2025, 1:00 AM EDT - 8 months ago

PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan

Jun 11, 2025, 2:00 AM EDT - 8 months ago

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

May 10, 2025, 11:57 PM EDT - 9 months ago

MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 10 months ago

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

Apr 10, 2025, 2:00 AM EDT - 11 months ago

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 15, 2025, 8:30 AM EDT - 1 year ago

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price

Mar 11, 2025, 7:52 PM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:05 PM EDT - 1 year ago

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

Feb 12, 2025, 2:00 AM EST - 1 year ago

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

Feb 7, 2025, 2:00 AM EST - 1 year ago

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Jan 30, 2025, 10:36 AM EST - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

Jan 30, 2025, 2:00 AM EST - 1 year ago

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Jan 13, 2025, 3:05 AM EST - 1 year ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Dec 23, 2024, 2:00 AM EST - 1 year ago

MaxCyte Announces Retirement of Board Member Art Mandell

Dec 9, 2024, 2:00 AM EST - 1 year ago

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

Nov 13, 2024, 8:05 AM EST - 1 year ago

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

Nov 6, 2024, 10:01 PM EST - 1 year ago

MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 1 year ago

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

Oct 31, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in Two Upcoming Investor Conferences

Oct 15, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Cynthia Collins to its Board of Directors

Oct 11, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

Oct 10, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

Oct 4, 2024, 5:19 PM EDT - 1 year ago

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up

Sep 16, 2024, 2:00 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

Sep 5, 2024, 4:05 PM EDT - 1 year ago

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

Aug 7, 2024, 12:09 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

Jul 9, 2024, 4:05 PM EDT - 1 year ago

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

May 29, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

May 22, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

May 11, 2024, 8:35 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

Apr 10, 2024, 8:05 AM EDT - 2 years ago

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 2, 2024, 8:05 AM EDT - 2 years ago

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Mar 12, 2024, 10:40 PM EDT - 2 years ago

MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 2 years ago

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

Mar 4, 2024, 4:05 PM EST - 2 years ago

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

BeefStewart Feb. 13 at 3:48 PM

$MXCT I worried for a moment. I thought things were actually starting to turn around, but now I see it's business as usual and the stock is plunging again on no news 🙄

0 · Reply

CH_Expat Feb. 13 at 2:39 PM

2 · Reply

BeefStewart Feb. 12 at 11:11 PM

0 · Reply

BeefStewart Feb. 12 at 9:18 PM

$MXCT $VRTX

0 · Reply

BeefStewart Feb. 12 at 9:02 PM

$MXCT

0 · Reply

BeefStewart Feb. 12 at 7:19 PM

$MXCT $VRTX At this point, I think direction is more valuable than absolute revenue from Casgevy. We want to see better cell collection and more treatment centers coming online.

0 · Reply

BeefStewart Feb. 12 at 6:02 PM

$MXCT Could we have actually, finally bottomed at $0.6806???

1 · Reply

BeefStewart Feb. 12 at 5:54 PM

$MXCT Initiate a Strategic Review. Buy back $5-$10M worth of shares. Entertain buyout offers of $2+ once the first 2 steps organically bring the share price over a dollar.

0 · Reply

Playtheplayers Feb. 12 at 5:16 PM

$MXCT thank you...

0 · Reply

BeefStewart Feb. 12 at 5:03 PM

$MXCT If this went to 0.01, would management do a share buyback? 🤔

1 · Reply

BeefStewart Feb. 12 at 4:57 PM

$MXCT $VRTX reports today. Expecting some color on Casgevy...

0 · Reply

BeefStewart Feb. 12 at 3:26 PM

$MXCT Just to recap: There is no bottom. The cash position is meaningless without growth. Management doesn't know how to stop the bleeding. Similar stocks including $CLPT are also suffering. The stock has dropped over 50 percent in a month and management has not pulled any levers to at least attempt to instill confidence in investors.

1 · Reply

CH_Expat Feb. 12 at 3:01 PM

$MXCT Time for another team event to turn things around.

0 · Reply

BeefStewart Feb. 12 at 3:00 PM

$MXCT @nomen looks to be right again. 0.60s incoming..

1 · Reply

RunningTime2025 Feb. 12 at 2:55 PM

$MXCT no point of return

0 · Reply

CH_Expat Feb. 12 at 1:46 PM

$MXCT Another max pain day in MaxShyte-Land is starting.

1 · Reply

Playtheplayers Feb. 11 at 9:39 PM

$MXCT Thank you... Mr. Market for slapping my stock form further. You thank him

0 · Reply

CH_Expat Feb. 11 at 7:05 PM

$MXCT Imagine you bought this shitco a year ago. Biblical book losses. And they have the nerve to publish funny company events on LinkedIn. Once I get my average back, I know what to do.

1 · Reply

BeefStewart Feb. 11 at 3:02 PM

$MXCT @nomen looks to be right again. It also looks like management won't be rescuing this from penny territory anytime soon.

1 · Reply

Playtheplayers Feb. 10 at 10:59 PM

$MXCT I did... I doubled my share count today. Give a little bit...... Give a little bit of your love to me!!! Sing it with me!

2 · Reply

BeefStewart Feb. 10 at 10:32 PM

$MXCT Per Fintel: Goldman increased holdings, while Bank of NY Mellon modestly reduced

0 · Reply

BeefStewart Feb. 10 at 10:17 PM

$MXCT Basically me remaining optimistic since the time this was dropping from October highs. 😭

0 · Reply

Market Cap	78.29M
Revenue (ttm)	38.63M
Net Income (ttm)	-41.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-106.29%
Debt to Equity Ratio	0.00

Volume	1,262,400
Avg Vol	1,243,056
Day's Range	N/A - N/A
Shares Out	106.67M
Stochastic %K	18%
Beta	1.21
Analysts	Strong Sell
Price Target	$7.00